CytoSorbents announces new European guidelines that consider hemoadsorption

CytoSorbents announces that hemoadsorption of antithrombotic drugs in cardiothoracic surgery has made its way into the new "2022 Guidelines for the Management of Severe Perioperative Bleeding" by the European Society of Anaesthesiology and Intensive Care, ESAIC, and was published in the European Journal of Anaesthesiology last week. The aim of this second update to the guidelines previously published in 2017, was to provide an evidence-based set of recommendations to aid in the clinical management of patients at risk of surgical bleeding in a variety of clinical situations. In Section 2.1, "How Should Intra-operative and Postoperative Bleeding be Stopped and Anaemia be Managed" in patients undergoing cardiovascular surgery, the committee reviewed published studies using CytoSorb to reduce bleeding complications in patients undergoing cardiac surgery on antithrombotic agents and made the following recommendation: "In patients on ticagrelor or rivaroxaban undergoing emergency cardiac/aortic surgery on CPB, haemoadsorption may be considered as an adjuvant therapy to reduce bleeding complications." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, added, "The recognition of hemoadsorption of blood thinning drugs in these guidelines is a nice validation of our DrugSorb-ATR(R) clinical program in the U.S. and Canada. Should the ongoing STAR-T pivotal randomized controlled trial demonstrate that the DrugSorb-ATR system, which uses an equivalent polymer technology as CytoSorb, can safely reduce bleeding complications in cardiothoracic surgery patients on Brilinta(R), we expect the data to not only support U.S. FDA and Health Canada marketing approval, but to also help establish our technologies as the standard of care therapy for this major unmet medical need in treatment guidelines worldwide."